{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:28:33Z","timestamp":1795040913849,"version":"4.10.2"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The breast cancer (BC)-related mortality is higher and the immunity is altered in women living with HIV (WLWH) compared to HIV-negative women. Therefore, tumor samples of 296 black BC patients from South Africa and Namibia with known age, HIV status, tumor stage, hormone receptor and HER2 status and overall survival (OS) are analyzed for components of the tumor microenvironment (TME). WLWH (<jats:italic>n<\/jats:italic>\u2009=\u2009117), either with suppressed viral activity (HR\u2009=\u20091.25) or with immune suppression (HR\u2009=\u20092.04), have a shorter OS. HIV status is associated with increased numbers of CD8<jats:sup>+<\/jats:sup> T cells in the TME compared to HIV-negative patients; no correlation is found with CD4<jats:sup>+<\/jats:sup> T cell numbers in the blood. Moreover, an increased expression of CD276\/B7-H3 and a more pronounced IFN-\u03b3 signaling in the tumors are found in WLWH, independent of age, stage, and BC subtypes. In conclusion, altered T cell composition and CD276 expression in WLWH may contribute to inferior survival and can be used for targeted treatment.<\/jats:p>","DOI":"10.1038\/s41467-025-59408-8","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:46:37Z","timestamp":1747755997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["HIV status alters immune cell infiltration and activation profile in women with breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Marcus","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3008-014X","authenticated-orcid":false,"given":"Pablo","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wilfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelle","family":"Zietsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6642-9585","authenticated-orcid":false,"given":"Martina","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Kaufhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wickenhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"dos-Santos-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-4906","authenticated-orcid":false,"given":"Wenlong Carl","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Cubasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1980-1805","authenticated-orcid":false,"given":"Nivashini","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5544-4958","authenticated-orcid":false,"given":"Barbara","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kantelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"59408_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941\u20131953 (2019).","journal-title":"Int. J. Cancer"},{"key":"59408_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650117","volume":"11","author":"Y Hamdi","year":"2021","unstructured":"Hamdi, Y. et al. Cancer in Africa: the untold story. Front. Oncol. 11, 650117 (2021).","journal-title":"Front. Oncol."},{"key":"59408_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"59408_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.breast.2018.08.095","volume":"42","author":"CM Weiner","year":"2018","unstructured":"Weiner, C. M. et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women. Breast Edinb. Scotl. 42, 23\u201330 (2018).","journal-title":"Breast Edinb. Scotl."},{"key":"59408_CR5","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/ijc.31187","volume":"142","author":"F McKenzie","year":"2018","unstructured":"McKenzie, F. et al. Drivers of advanced stage at breast cancer diagnosis in the multicountry African breast cancer - disparities in outcomes (ABC-DO) study. Int. J. Cancer 142, 1568\u20131579 (2018).","journal-title":"Int. J. Cancer"},{"key":"59408_CR6","doi-asserted-by":"publisher","first-page":"e1203","DOI":"10.1016\/S2214-109X(20)30261-8","volume":"8","author":"V McCormack","year":"2020","unstructured":"McCormack, V. et al. Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): a prospective cohort study. Lancet Glob. Health 8, e1203\u2013e1212 (2020).","journal-title":"Lancet Glob. Health"},{"key":"59408_CR7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/2326-6066.CIR-22-0795","volume":"11","author":"M Bauer","year":"2023","unstructured":"Bauer, M. et al. Regional variation in the tumor microenvironment, immune escape and prognostic factors in breast cancer in Sub-Saharan Africa. Cancer Immunol. Res. 11, 720\u2013731 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"59408_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13058-023-01627-2","volume":"25","author":"M Miyashita","year":"2023","unstructured":"Miyashita, M. et al. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 25, 58 (2023).","journal-title":"Breast Cancer Res."},{"key":"59408_CR9","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1158\/2159-8290.CD-22-0138","volume":"12","author":"R Martini","year":"2022","unstructured":"Martini, R. et al. African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in Women of African Descent. Cancer Discov. 12, 2530\u20132551 (2022).","journal-title":"Cancer Discov."},{"key":"59408_CR10","first-page":"1","volume":"4","author":"S Grover","year":"2018","unstructured":"Grover, S. et al. Breast cancer and HIV in Sub-Saharan Africa: a complex relationship. J. Glob. Oncol. 4, 1\u201311 (2018). Sep.","journal-title":"J. Glob. Oncol."},{"key":"59408_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02639-z","volume":"20","author":"E Haeuser","year":"2022","unstructured":"Haeuser, E. et al. Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018. BMC Med. 20, 488 (2022).","journal-title":"BMC Med."},{"key":"59408_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/1871526517666170505122800","volume":"18","author":"DY Lu","year":"2018","unstructured":"Lu, D. Y. et al. HAART in HIV\/AIDS treatments: future trends. Infect. Disord. Drug Targets 18, 15\u201322 (2018).","journal-title":"Infect. Disord. Drug Targets"},{"key":"59408_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2020.09.004","volume":"183","author":"S Agarwal-Jans","year":"2020","unstructured":"Agarwal-Jans, S. Timeline: HIV. Cell 183, 550 (2020).","journal-title":"Cell"},{"key":"59408_CR14","doi-asserted-by":"publisher","first-page":"e831","DOI":"10.1016\/S2352-3018(19)30196-1","volume":"6","author":"GBD 2017 HIV collaborators.","year":"2019","unstructured":"GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet Hiv. 6, e831\u2013e859 (2019).","journal-title":"Lancet Hiv."},{"key":"59408_CR15","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3018(21)00326-X","volume":"9","author":"S Chasimpha","year":"2022","unstructured":"Chasimpha, S. et al. Disparities in breast cancer survival between women with and without HIV across sub-Saharan Africa (ABC-DO): a prospective, cohort study. Lancet Hiv. 9, e160\u2013e171 (2022).","journal-title":"Lancet Hiv."},{"key":"59408_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00330","volume":"9","author":"S Chasimpha","year":"2023","unstructured":"Chasimpha, S. et al. Survival disparities between patients with breast cancer with and without HIV: a research framework. JCO Glob. Oncol. 9, e2200330 (2023).","journal-title":"JCO Glob. Oncol."},{"key":"59408_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ijc.33981","volume":"151","author":"OA Ayeni","year":"2022","unstructured":"Ayeni, O. A. et al. Impact of HIV infection on survival among women with stage I-III breast cancer: results from the South African breast cancer and HIV outcomes study. Int. J. Cancer 151, 209\u2013221 (2022).","journal-title":"Int. J. Cancer"},{"key":"59408_CR18","doi-asserted-by":"publisher","first-page":"e1993","DOI":"10.1016\/S2214-109X(24)00376-0","volume":"12","author":"J Dubner","year":"2024","unstructured":"Dubner, J. et al. The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort study. Lancet Glob. Health 12, e1993\u2013e2002 (2024).","journal-title":"Lancet Glob. Health"},{"key":"59408_CR19","doi-asserted-by":"publisher","first-page":"e004564","DOI":"10.1136\/jitc-2022-004564","volume":"10","author":"O Chaudhary","year":"2022","unstructured":"Chaudhary, O. et al. Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis. J. Immunother. Cancer 10, e004564 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"59408_CR20","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3390\/ijms19072000","volume":"19","author":"M Sperk","year":"2018","unstructured":"Sperk, M., Domselaar, Rvan & Neogi, U. Immune checkpoints as the immune system regulators and potential biomarkers in HIV-1 Iinfection. Int. J. Mol. Sci. 19, 2000 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"59408_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.553983","volume":"10","author":"G Curty","year":"2020","unstructured":"Curty, G. et al. Human endogenous retrovirus expression is upregulated in the breast cancer microenvironment of HIV infected women: a pilot study. Front. Oncol. 10, 553983 (2020).","journal-title":"Front. Oncol."},{"key":"59408_CR22","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1097\/01.aids.0000238411.75324.59","volume":"20","author":"EA Engels","year":"2006","unstructured":"Engels, E. A. et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS Lond. Engl. 20, 1645\u20131654 (2006).","journal-title":"AIDS Lond. Engl."},{"key":"59408_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"59408_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41568-023-00594-2","volume":"23","author":"G El Tekle","year":"2023","unstructured":"El Tekle, G. & Garrett, W. S. Bacteria in cancer initiation, promotion and progression. Nat. Rev. Cancer 23, 600\u2013618 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"59408_CR25","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.3390\/ijms24097803","volume":"24","author":"M Costanzo","year":"2023","unstructured":"Costanzo, M., De Giglio, M. A. R. & Roviello, G. N. Deciphering the relationship between SARS-CoV-2 and cancer. Int. J. Mol. Sci. 24, 7803 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"59408_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29236","volume":"95","author":"E Akbari","year":"2023","unstructured":"Akbari, E., Milani, A., Seyedinkhorasani, M. & Bolhassani, A. HPV co-infections with other pathogens in cancer development: a comprehensive review. J. Med. Virol. 95, e29236 (2023).","journal-title":"J. Med. Virol."},{"key":"59408_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"59408_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/ol.2022.13625","volume":"25","author":"YP Sun","year":"2023","unstructured":"Sun, Y. P., Ke, Y. L. & Li, X. Prognostic value of CD8+ tumor-infiltrating T cells in patients with breast cancer: a systematic review and meta-analysis. Oncol. Lett. 25, 39 (2023).","journal-title":"Oncol. Lett."},{"key":"59408_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153963","volume":"7","author":"CA Egelston","year":"2022","unstructured":"Egelston, C. A. et al. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor\u2013positive breast cancer. JCI Insight 7, e153963 (2022).","journal-title":"JCI Insight"},{"key":"59408_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep10775","volume":"5","author":"A Koussounadis","year":"2015","unstructured":"Koussounadis, A., Langdon, S. P., Um, I. H., Harrison, D. J. & Smith, V. A. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Sci. Rep. 5, 10775 (2015).","journal-title":"Sci. Rep."},{"key":"59408_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-365","volume":"10","author":"M Gry","year":"2009","unstructured":"Gry, M. et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genom. 10, 365 (2009).","journal-title":"BMC Genom."},{"key":"59408_CR32","doi-asserted-by":"publisher","first-page":"a028423","DOI":"10.1101\/cshperspect.a028423","volume":"10","author":"H Negishi","year":"2018","unstructured":"Negishi, H., Taniguchi, T. & Yanai, H. The Interferon (IFN) class of cytokines and the IFN Regulatory Factor (IRF) transcription factor family. Cold Spring Harb. Perspect. Biol. 10, a028423 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"59408_CR33","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.4049\/jimmunol.139.4.1104","volume":"139","author":"GJ Bancroft","year":"1987","unstructured":"Bancroft, G. J., Schreiber, R. D., Bosma, G. C., Bosma, M. J. & Unanue, E. R. A T cell-independent mechanism of macrophage activation by interferon-gamma. J. Immunol. 139, 1104\u20131107 (1987).","journal-title":"J. Immunol."},{"key":"59408_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","volume":"17","author":"NR Maimela","year":"2019","unstructured":"Maimela, N. R., Liu, S. & Zhang, Y. Fates of CD8+ T cells in tumor microenvironment. Comput. Struct. Biotechnol. J. 17, 1\u201313 (2019).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"59408_CR35","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/blood-2010-07-294702","volume":"117","author":"Y Kannan","year":"2011","unstructured":"Kannan, Y. et al. I\u03baB\u03b6 augments IL-12- and IL-18-mediated IFN-\u03b3 production in human NK cells. Blood 117, 2855\u20132863 (2011).","journal-title":"Blood"},{"key":"59408_CR36","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.4049\/jimmunol.1400348","volume":"193","author":"MP Hosking","year":"2014","unstructured":"Hosking, M. P., Flynn, C. T. & Whitton, J. L. Antigen-specific naive CD8+ T cells produce a single pulse of IFN-\u03b3 in vivo within hours of infection, but without antiviral effect. J. Immunol. 193, 1873\u20131885 (2014). Aug 15.","journal-title":"J. Immunol."},{"key":"59408_CR37","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1128\/JVI.01844-08","volume":"83","author":"AR Stacey","year":"2009","unstructured":"Stacey, A. R. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83, 3719\u20133733 (2009).","journal-title":"J. Virol."},{"key":"59408_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fimmu.2013.00498","volume":"4","author":"SR Roff","year":"2014","unstructured":"Roff, S. R., Noon-Song, E. N. & Yamamoto, J. K. The Significance of Interferon-\u03b3 in HIV-1 pathogenesis, therapy, and prophylaxis. Front. Immunol. 4, 498 (2014).","journal-title":"Front. Immunol."},{"key":"59408_CR39","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1128\/JVI.77.12.6867-6878.2003","volume":"77","author":"J Cao","year":"2003","unstructured":"Cao, J. et al. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J. Virol. 77, 6867\u20136878 (2003).","journal-title":"J. Virol."},{"key":"59408_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1089\/vim.2010.0065","volume":"23","author":"D Watanabe","year":"2010","unstructured":"Watanabe, D. et al. Sustained high levels of serum interferon-\u03b3 during HIV-1 infection: a specific trend different from other cytokines. Viral Immunol. 23, 619\u2013625 (2010).","journal-title":"Viral Immunol."},{"key":"59408_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-\u03b3: teammate or opponent in the tumour microenvironment? Nat. Rev. Immunol. 22, 158\u2013172 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"59408_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35948-9","volume":"14","author":"JM Mazet","year":"2023","unstructured":"Mazet, J. M. et al. IFN\u03b3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. Nat. Commun. 14, 321 (2023).","journal-title":"Nat. Commun."},{"key":"59408_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 Therapy. Cell 167, 397\u2013404.e9 (2016).","journal-title":"Cell"},{"key":"59408_CR44","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s00432-022-04201-z","volume":"149","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Interferon-\u03b3 predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. J. Cancer Res. Clin. Oncol. 149, 3043\u20133050 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"59408_CR45","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1210\/jcem-62-6-1101","volume":"62","author":"IL Campbell","year":"1986","unstructured":"Campbell, I. L., Bizilj, K., Colman, P. G., Tuch, B. E. & Harrison, L. C. Interferon-gamma induces the expression of HLA-A,B,C but not HLA-DR on human pancreatic beta-cells. J. Clin. Endocrinol. Metab. 62, 1101\u20131109 (1986).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"59408_CR46","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1158\/1078-0432.CCR-10-2114","volume":"17","author":"A Respa","year":"2011","unstructured":"Respa, A. et al. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 17, 2668\u20132678 (2011).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"59408_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6145-8","volume":"19","author":"G Ding","year":"2019","unstructured":"Ding, G. et al. IFN-\u03b3 down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. BMC Cancer 19, 1053 (2019).","journal-title":"BMC Cancer"},{"key":"59408_CR48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4049\/jimmunol.161.1.489","volume":"161","author":"E Scala","year":"1998","unstructured":"Scala, E. et al. Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations. J. Immunol. 161, 489\u2013493 (1998).","journal-title":"J. Immunol."},{"key":"59408_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark. Res. 8, 49 (2020).","journal-title":"Biomark. Res."},{"key":"59408_CR50","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1002\/cam4.1700","volume":"7","author":"L Ni","year":"2018","unstructured":"Ni, L. & Lu, J. Interferon gamma in cancer immunotherapy. Cancer Med. 7, 4509\u20134516 (2018).","journal-title":"Cancer Med."},{"key":"59408_CR51","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni967","volume":"4","author":"WK Suh","year":"2003","unstructured":"Suh, W. K. et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4, 899\u2013906 (2003).","journal-title":"Nat. Immunol."},{"key":"59408_CR52","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.tripleo.2008.08.012","volume":"106","author":"HY Yang","year":"2008","unstructured":"Yang, H. Y. et al. Transgenic B7-H3 therapy induces tumor-specific immune response in human oral squamous cell cancer: an in vitro study. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod. 106, 721\u2013728 (2008).","journal-title":"Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod."},{"key":"59408_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36881-7","volume":"14","author":"HJ Liu","year":"2023","unstructured":"Liu, H. J. et al. mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Nat. Commun. 14, 1214 (2023).","journal-title":"Nat. Commun."},{"key":"59408_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbrc.2019.04.142","volume":"514","author":"C Chen","year":"2019","unstructured":"Chen, C. et al. Frequent B7-H3 overexpression in craniopharyngioma. Biochem. Biophys. Res. Commun. 514, 379\u2013385 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"59408_CR55","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/cancers13020186","volume":"13","author":"M Bauer","year":"2021","unstructured":"Bauer, M. et al. Altered spatial composition of the immune cell repertoire in association to CD34+ blasts in myelodysplastic syndromes and secondary acute myeloid leukemia. Cancers 13, 186 (2021).","journal-title":"Cancers"},{"key":"59408_CR56","doi-asserted-by":"crossref","unstructured":"Feng, Z. et al. Multiparametric immune profiling in HPV- oral squamous cell cancer. JCI Insight. 2, e93652 (2017).","DOI":"10.1172\/jci.insight.93652"},{"key":"59408_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2323212","volume":"13","author":"M Bauer","year":"2024","unstructured":"Bauer, M. et al. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML. OncoImmunology 13, 2323212 (2024).","journal-title":"OncoImmunology"},{"key":"59408_CR58","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos, F. et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 27, 1227\u20131235 (2021).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"59408_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","volume":"12","author":"WT Zhou","year":"2021","unstructured":"Zhou, W. T. & Jin, W. L. B7-H3\/CD276: an emerging cancer immunotherapy. Front. Immunol. 12, 701006 (2021).","journal-title":"Front. Immunol."},{"key":"59408_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/JIPO-23-18","volume":"7","author":"K Feustel","year":"2024","unstructured":"Feustel, K., Martin, J. & Falchook, G. S. B7-H3 inhibitors in oncology clinical trials: a review. J. Immunother. Precis Oncol. 7, 53\u201366 (2024).","journal-title":"J. Immunother. Precis Oncol."},{"key":"59408_CR61","doi-asserted-by":"publisher","first-page":"e004424","DOI":"10.1136\/jitc-2021-004424","volume":"10","author":"C Aggarwal","year":"2022","unstructured":"Aggarwal, C. et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial. J. Immunother. Cancer 10, e004424 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"59408_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10229-8","volume":"22","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. BMC Cancer 22, 1124 (2022).","journal-title":"BMC Cancer"},{"key":"59408_CR63","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/S2352-3018(23)00272-2","volume":"11","author":"A Trickey","year":"2024","unstructured":"Trickey, A. et al. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies. Lancet Hiv. 11, e176\u2013e185 (2024).","journal-title":"Lancet Hiv."},{"key":"59408_CR64","first-page":"328","volume":"3","author":"RL Smith","year":"2012","unstructured":"Smith, R. L., de Boer, R., Brul, S., Budovskaya, Y. & van Spek, H. Premature and accelerated aging: HIV or HAART? Front. Genet. 3, 328 (2012).","journal-title":"Front. Genet."},{"key":"59408_CR65","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nrd1151","volume":"2","author":"A Carr","year":"2003","unstructured":"Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2, 624\u2013634 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"59408_CR66","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0168-8278(01)00311-7","volume":"36","author":"U Spengler","year":"2002","unstructured":"Spengler, U., Lichterfeld, M. & Rockstroh, J. K. Antiretroviral drug toxicity - a challenge for the hepatologist? J. Hepatol. 36, 283\u2013294 (2002).","journal-title":"J. Hepatol."},{"key":"59408_CR67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JGO.2015.002675","volume":"3","author":"H Cubasch","year":"2017","unstructured":"Cubasch, H. et al. South African breast cancer and hiv outcomes study: methods and baseline assessment. J. Glob. Oncol. 3, 114\u2013124 (2017).","journal-title":"J. Glob. Oncol."},{"key":"59408_CR68","doi-asserted-by":"publisher","first-page":"e011390","DOI":"10.1136\/bmjopen-2016-011390","volume":"6","author":"F McKenzie","year":"2016","unstructured":"McKenzie, F. et al. African Breast Cancer-Disparities in Outcomes (ABC-DO): protocol of a multicountry mobile health prospective study of breast cancer survival in sub-Saharan Africa. BMJ Open. 6, e011390 (2016).","journal-title":"BMJ Open."},{"key":"59408_CR69","unstructured":"WHO Classification of Tumours Editorial Board. Breast tumours. WHO Classification of Tumours. 5th ed. Vol. 2 (OMS, Geneva, 2019)."},{"key":"59408_CR70","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1529::AID-CNCR7>3.0.CO;2-V","volume":"83","author":"SE Pinder","year":"1998","unstructured":"Pinder, S. E. et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 83, 1529\u20131539 (1998).","journal-title":"Cancer"},{"key":"59408_CR71","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch, A. et al. Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 22, 1736\u20131747 (2011).","journal-title":"Ann. Oncol."},{"key":"59408_CR72","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline Update. J. Clin. Oncol. 38, 1346\u20131366 (2020).","journal-title":"J. Clin. Oncol."},{"key":"59408_CR73","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J. Clin. Oncol. 41, 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"key":"59408_CR74","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3390\/biomedicines9121842","volume":"9","author":"FL Sch\u00fcmann","year":"2021","unstructured":"Sch\u00fcmann, F. L. et al. Divergent effects of EZH1 and EZH2 protein expression on the prognosis of patients with T-Cell lymphomas. Biomedicines 9, 1842 (2021).","journal-title":"Biomedicines"},{"key":"59408_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.mie.2019.05.055","volume":"635","author":"M Bauer","year":"2020","unstructured":"Bauer, M. et al. Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche. Methods Enzymol. 635, 67\u201379 (2020).","journal-title":"Methods Enzymol."},{"key":"59408_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59408-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59408-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59408-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T17:03:34Z","timestamp":1747760614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59408-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59408"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59408-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4699"}}